

Global Pharmaceutical CMO and CDMO Market 2023 by Company, Regions, Type and Application, Forecast to 2029

https://marketpublishers.com/r/GB2813B4E2A6EN.html

Date: August 2024

Pages: 123

Price: US\$ 3,480.00 (Single User License)

ID: GB2813B4E2A6EN

Abstracts

According to our (Global Info Research) latest study, the global Pharmaceutical CMO and CDMO market size was valued at USD 131990 million in 2022 and is forecast to a readjusted size of USD 216840 million by 2029 with a CAGR of 7.3% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The market driver is consistent development of blockbuster pharmaceuticals, increasing production outsourcing by pharmaceuticals companies. The increasing outsourcing trend in the pharmaceutical industry demonstrates the success of this business model, as CDMOs are increasingly becoming integral parts of pharmaceutical companies' value chains.

A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.

This report is a detailed and comprehensive analysis for global Pharmaceutical CMO and CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.



Key Features:

Global Pharmaceutical CMO and CDMO market size and forecasts, in consumption value (\$ Million), 2018-2029

Global Pharmaceutical CMO and CDMO market size and forecasts by region and country, in consumption value (\$ Million), 2018-2029

Global Pharmaceutical CMO and CDMO market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2018-2029

Global Pharmaceutical CMO and CDMO market shares of main players, in revenue (\$ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Pharmaceutical CMO and CDMO

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Pharmaceutical CMO and CDMO market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics and Fareva, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Pharmaceutical CMO and CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you



narkets.

| expand | d your business by targeting qualified niche m |
|--------|--|
| Market | segment by Type |
| | API CMO and CDMO |
| | FDF CMO and CDMO |
| | Packaging CMO |
| | Clinical CDMO |
| Market | segment by Application |
| | Pharmaceutical Company |
| | Biotechnology Company |
| | Other |
| Market | segment by players, this report covers |
| | Lonza |
| | Catalent |
| | Thermo Fisher Scientific |
| | Samsung Biologics |
| | Fareva |
| | WuXi AppTech |
| | WuXi Biologics |
| | |

Siegfried



| FUJIFILM Diosynth Biotechnologies | | |
|-----------------------------------|--|--|
| Asymchem | | |
| Pfizer CentreOne | | |
| Delpharm | | |
| Recipharm | | |
| AGC Pharma Chemicals | | |
| Boehringer Ingelheim | | |
| Vetter | | |
| Curia | | |
| Aenova | | |
| Porton | | |
| Piramal | | |
| Strides Pharma | | |
| NextPharma | | |
| Famar | | |
| Jubilant | | |
| Alcami | | |
| Euroapi | | |
| Eurofins | | |



Avid Bioservices

BioVectra

CPL

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Pharmaceutical CMO and CDMO product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Pharmaceutical CMO and CDMO, with revenue, gross margin and global market share of Pharmaceutical CMO and CDMO from 2018 to 2023.

Chapter 3, the Pharmaceutical CMO and CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Pharmaceutical CMO and CDMO market forecast, by regions, type and application, with



consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Pharmaceutical CMO and CDMO.

Chapter 13, to describe Pharmaceutical CMO and CDMO research findings and conclusion.



Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Pharmaceutical CMO and CDMO
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Pharmaceutical CMO and CDMO by Type
- 1.3.1 Overview: Global Pharmaceutical CMO and CDMO Market Size by Type: 2018 Versus 2022 Versus 2029
- 1.3.2 Global Pharmaceutical CMO and CDMO Consumption Value Market Share by Type in 2022
 - 1.3.3 API CMO and CDMO
 - 1.3.4 FDF CMO and CDMO
 - 1.3.5 Packaging CMO
 - 1.3.6 Clinical CDMO
- 1.4 Global Pharmaceutical CMO and CDMO Market by Application
- 1.4.1 Overview: Global Pharmaceutical CMO and CDMO Market Size by Application:
- 2018 Versus 2022 Versus 2029
 - 1.4.2 Pharmaceutical Company
 - 1.4.3 Biotechnology Company
 - 1.4.4 Other
- 1.5 Global Pharmaceutical CMO and CDMO Market Size & Forecast
- 1.6 Global Pharmaceutical CMO and CDMO Market Size and Forecast by Region
- 1.6.1 Global Pharmaceutical CMO and CDMO Market Size by Region: 2018 VS 2022 VS 2029
 - 1.6.2 Global Pharmaceutical CMO and CDMO Market Size by Region, (2018-2029)
- 1.6.3 North America Pharmaceutical CMO and CDMO Market Size and Prospect (2018-2029)
 - 1.6.4 Europe Pharmaceutical CMO and CDMO Market Size and Prospect (2018-2029)
- 1.6.5 Asia-Pacific Pharmaceutical CMO and CDMO Market Size and Prospect (2018-2029)
- 1.6.6 South America Pharmaceutical CMO and CDMO Market Size and Prospect (2018-2029)
- 1.6.7 Middle East and Africa Pharmaceutical CMO and CDMO Market Size and Prospect (2018-2029)

2 COMPANY PROFILES

2.1 Lonza



- 2.1.1 Lonza Details
- 2.1.2 Lonza Major Business
- 2.1.3 Lonza Pharmaceutical CMO and CDMO Product and Solutions
- 2.1.4 Lonza Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.1.5 Lonza Recent Developments and Future Plans
- 2.2 Catalent
 - 2.2.1 Catalent Details
 - 2.2.2 Catalent Major Business
 - 2.2.3 Catalent Pharmaceutical CMO and CDMO Product and Solutions
- 2.2.4 Catalent Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.2.5 Catalent Recent Developments and Future Plans
- 2.3 Thermo Fisher Scientific
 - 2.3.1 Thermo Fisher Scientific Details
 - 2.3.2 Thermo Fisher Scientific Major Business
 - 2.3.3 Thermo Fisher Scientific Pharmaceutical CMO and CDMO Product and Solutions
- 2.3.4 Thermo Fisher Scientific Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.3.5 Thermo Fisher Scientific Recent Developments and Future Plans
- 2.4 Samsung Biologics
 - 2.4.1 Samsung Biologics Details
 - 2.4.2 Samsung Biologics Major Business
 - 2.4.3 Samsung Biologics Pharmaceutical CMO and CDMO Product and Solutions
- 2.4.4 Samsung Biologics Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.4.5 Samsung Biologics Recent Developments and Future Plans
- 2.5 Fareva
 - 2.5.1 Fareva Details
 - 2.5.2 Fareva Major Business
 - 2.5.3 Fareva Pharmaceutical CMO and CDMO Product and Solutions
- 2.5.4 Fareva Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.5.5 Fareva Recent Developments and Future Plans
- 2.6 WuXi AppTech
 - 2.6.1 WuXi AppTech Details
 - 2.6.2 WuXi AppTech Major Business
 - 2.6.3 WuXi AppTech Pharmaceutical CMO and CDMO Product and Solutions
 - 2.6.4 WuXi AppTech Pharmaceutical CMO and CDMO Revenue, Gross Margin and



Market Share (2018-2023)

- 2.6.5 WuXi AppTech Recent Developments and Future Plans
- 2.7 WuXi Biologics
 - 2.7.1 WuXi Biologics Details
 - 2.7.2 WuXi Biologics Major Business
 - 2.7.3 WuXi Biologics Pharmaceutical CMO and CDMO Product and Solutions
- 2.7.4 WuXi Biologics Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.7.5 WuXi Biologics Recent Developments and Future Plans
- 2.8 Siegfried
 - 2.8.1 Siegfried Details
 - 2.8.2 Siegfried Major Business
 - 2.8.3 Siegfried Pharmaceutical CMO and CDMO Product and Solutions
- 2.8.4 Siegfried Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
- 2.8.5 Siegfried Recent Developments and Future Plans
- 2.9 FUJIFILM Diosynth Biotechnologies
 - 2.9.1 FUJIFILM Diosynth Biotechnologies Details
 - 2.9.2 FUJIFILM Diosynth Biotechnologies Major Business
- 2.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CMO and CDMO Product and Solutions
- 2.9.4 FUJIFILM Diosynth Biotechnologies Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
- 2.10 Asymchem
 - 2.10.1 Asymchem Details
 - 2.10.2 Asymchem Major Business
 - 2.10.3 Asymchem Pharmaceutical CMO and CDMO Product and Solutions
- 2.10.4 Asymchem Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.10.5 Asymchem Recent Developments and Future Plans
- 2.11 Pfizer CentreOne
 - 2.11.1 Pfizer CentreOne Details
 - 2.11.2 Pfizer CentreOne Major Business
 - 2.11.3 Pfizer CentreOne Pharmaceutical CMO and CDMO Product and Solutions
- 2.11.4 Pfizer CentreOne Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.11.5 Pfizer CentreOne Recent Developments and Future Plans
- 2.12 Delpharm



- 2.12.1 Delpharm Details
- 2.12.2 Delpharm Major Business
- 2.12.3 Delpharm Pharmaceutical CMO and CDMO Product and Solutions
- 2.12.4 Delpharm Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
- 2.12.5 Delpharm Recent Developments and Future Plans
- 2.13 Recipharm
 - 2.13.1 Recipharm Details
 - 2.13.2 Recipharm Major Business
 - 2.13.3 Recipharm Pharmaceutical CMO and CDMO Product and Solutions
- 2.13.4 Recipharm Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.13.5 Recipharm Recent Developments and Future Plans
- 2.14 AGC Pharma Chemicals
 - 2.14.1 AGC Pharma Chemicals Details
 - 2.14.2 AGC Pharma Chemicals Major Business
- 2.14.3 AGC Pharma Chemicals Pharmaceutical CMO and CDMO Product and Solutions
- 2.14.4 AGC Pharma Chemicals Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.14.5 AGC Pharma Chemicals Recent Developments and Future Plans
- 2.15 Boehringer Ingelheim
 - 2.15.1 Boehringer Ingelheim Details
 - 2.15.2 Boehringer Ingelheim Major Business
 - 2.15.3 Boehringer Ingelheim Pharmaceutical CMO and CDMO Product and Solutions
- 2.15.4 Boehringer Ingelheim Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.15.5 Boehringer Ingelheim Recent Developments and Future Plans
- 2.16 Vetter
 - 2.16.1 Vetter Details
 - 2.16.2 Vetter Major Business
 - 2.16.3 Vetter Pharmaceutical CMO and CDMO Product and Solutions
- 2.16.4 Vetter Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.16.5 Vetter Recent Developments and Future Plans
- 2.17 Curia
 - 2.17.1 Curia Details
 - 2.17.2 Curia Major Business
 - 2.17.3 Curia Pharmaceutical CMO and CDMO Product and Solutions



- 2.17.4 Curia Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.17.5 Curia Recent Developments and Future Plans
- 2.18 Aenova
 - 2.18.1 Aenova Details
 - 2.18.2 Aenova Major Business
 - 2.18.3 Aenova Pharmaceutical CMO and CDMO Product and Solutions
- 2.18.4 Aenova Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
- 2.18.5 Aenova Recent Developments and Future Plans
- 2.19 Porton
 - 2.19.1 Porton Details
 - 2.19.2 Porton Major Business
 - 2.19.3 Porton Pharmaceutical CMO and CDMO Product and Solutions
- 2.19.4 Porton Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.19.5 Porton Recent Developments and Future Plans
- 2.20 Piramal
 - 2.20.1 Piramal Details
 - 2.20.2 Piramal Major Business
 - 2.20.3 Piramal Pharmaceutical CMO and CDMO Product and Solutions
- 2.20.4 Piramal Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.20.5 Piramal Recent Developments and Future Plans
- 2.21 Strides Pharma
 - 2.21.1 Strides Pharma Details
 - 2.21.2 Strides Pharma Major Business
 - 2.21.3 Strides Pharma Pharmaceutical CMO and CDMO Product and Solutions
- 2.21.4 Strides Pharma Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.21.5 Strides Pharma Recent Developments and Future Plans
- 2.22 NextPharma
 - 2.22.1 NextPharma Details
 - 2.22.2 NextPharma Major Business
 - 2.22.3 NextPharma Pharmaceutical CMO and CDMO Product and Solutions
- 2.22.4 NextPharma Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.22.5 NextPharma Recent Developments and Future Plans
- 2.23 Famar



- 2.23.1 Famar Details
- 2.23.2 Famar Major Business
- 2.23.3 Famar Pharmaceutical CMO and CDMO Product and Solutions
- 2.23.4 Famar Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.23.5 Famar Recent Developments and Future Plans
- 2.24 Jubilant
 - 2.24.1 Jubilant Details
 - 2.24.2 Jubilant Major Business
 - 2.24.3 Jubilant Pharmaceutical CMO and CDMO Product and Solutions
- 2.24.4 Jubilant Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.24.5 Jubilant Recent Developments and Future Plans
- 2.25 Alcami
 - 2.25.1 Alcami Details
 - 2.25.2 Alcami Major Business
 - 2.25.3 Alcami Pharmaceutical CMO and CDMO Product and Solutions
- 2.25.4 Alcami Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.25.5 Alcami Recent Developments and Future Plans
- 2.26 Euroapi
 - 2.26.1 Euroapi Details
 - 2.26.2 Euroapi Major Business
 - 2.26.3 Euroapi Pharmaceutical CMO and CDMO Product and Solutions
- 2.26.4 Euroapi Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.26.5 Euroapi Recent Developments and Future Plans
- 2.27 Eurofins
 - 2.27.1 Eurofins Details
 - 2.27.2 Eurofins Major Business
 - 2.27.3 Eurofins Pharmaceutical CMO and CDMO Product and Solutions
- 2.27.4 Eurofins Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.27.5 Eurofins Recent Developments and Future Plans
- 2.28 Avid Bioservices
 - 2.28.1 Avid Bioservices Details
 - 2.28.2 Avid Bioservices Major Business
 - 2.28.3 Avid Bioservices Pharmaceutical CMO and CDMO Product and Solutions
- 2.28.4 Avid Bioservices Pharmaceutical CMO and CDMO Revenue, Gross Margin and



Market Share (2018-2023)

- 2.28.5 Avid Bioservices Recent Developments and Future Plans
- 2.29 BioVectra
 - 2.29.1 BioVectra Details
 - 2.29.2 BioVectra Major Business
 - 2.29.3 BioVectra Pharmaceutical CMO and CDMO Product and Solutions
- 2.29.4 BioVectra Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
 - 2.29.5 BioVectra Recent Developments and Future Plans
- 2.30 CPL
 - 2.30.1 CPL Details
 - 2.30.2 CPL Major Business
 - 2.30.3 CPL Pharmaceutical CMO and CDMO Product and Solutions
- 2.30.4 CPL Pharmaceutical CMO and CDMO Revenue, Gross Margin and Market Share (2018-2023)
- 2.30.5 CPL Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

- 3.1 Global Pharmaceutical CMO and CDMO Revenue and Share by Players (2018-2023)
- 3.2 Market Share Analysis (2022)
 - 3.2.1 Market Share of Pharmaceutical CMO and CDMO by Company Revenue
- 3.2.2 Top 3 Pharmaceutical CMO and CDMO Players Market Share in 2022
- 3.2.3 Top 6 Pharmaceutical CMO and CDMO Players Market Share in 2022
- 3.3 Pharmaceutical CMO and CDMO Market: Overall Company Footprint Analysis
 - 3.3.1 Pharmaceutical CMO and CDMO Market: Region Footprint
 - 3.3.2 Pharmaceutical CMO and CDMO Market: Company Product Type Footprint
- 3.3.3 Pharmaceutical CMO and CDMO Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

- 4.1 Global Pharmaceutical CMO and CDMO Consumption Value and Market Share by Type (2018-2023)
- 4.2 Global Pharmaceutical CMO and CDMO Market Forecast by Type (2024-2029)



5 MARKET SIZE SEGMENT BY APPLICATION

- 5.1 Global Pharmaceutical CMO and CDMO Consumption Value Market Share by Application (2018-2023)
- 5.2 Global Pharmaceutical CMO and CDMO Market Forecast by Application (2024-2029)

6 NORTH AMERICA

- 6.1 North America Pharmaceutical CMO and CDMO Consumption Value by Type (2018-2029)
- 6.2 North America Pharmaceutical CMO and CDMO Consumption Value by Application (2018-2029)
- 6.3 North America Pharmaceutical CMO and CDMO Market Size by Country
- 6.3.1 North America Pharmaceutical CMO and CDMO Consumption Value by Country (2018-2029)
- 6.3.2 United States Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
- 6.3.3 Canada Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
 - 6.3.4 Mexico Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)

7 EUROPE

- 7.1 Europe Pharmaceutical CMO and CDMO Consumption Value by Type (2018-2029)
- 7.2 Europe Pharmaceutical CMO and CDMO Consumption Value by Application (2018-2029)
- 7.3 Europe Pharmaceutical CMO and CDMO Market Size by Country
- 7.3.1 Europe Pharmaceutical CMO and CDMO Consumption Value by Country (2018-2029)
- 7.3.2 Germany Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
 - 7.3.3 France Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
- 7.3.4 United Kingdom Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
 - 7.3.5 Russia Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
- 7.3.6 Italy Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)

8 ASIA-PACIFIC



- 8.1 Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value by Type (2018-2029)
- 8.2 Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value by Application (2018-2029)
- 8.3 Asia-Pacific Pharmaceutical CMO and CDMO Market Size by Region
- 8.3.1 Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value by Region (2018-2029)
 - 8.3.2 China Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
- 8.3.3 Japan Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
- 8.3.4 South Korea Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
 - 8.3.5 India Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
- 8.3.6 Southeast Asia Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
- 8.3.7 Australia Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)

9 SOUTH AMERICA

- 9.1 South America Pharmaceutical CMO and CDMO Consumption Value by Type (2018-2029)
- 9.2 South America Pharmaceutical CMO and CDMO Consumption Value by Application (2018-2029)
- 9.3 South America Pharmaceutical CMO and CDMO Market Size by Country
- 9.3.1 South America Pharmaceutical CMO and CDMO Consumption Value by Country (2018-2029)
 - 9.3.2 Brazil Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
- 9.3.3 Argentina Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)

10 MIDDLE EAST & AFRICA

- 10.1 Middle East & Africa Pharmaceutical CMO and CDMO Consumption Value by Type (2018-2029)
- 10.2 Middle East & Africa Pharmaceutical CMO and CDMO Consumption Value by Application (2018-2029)
- 10.3 Middle East & Africa Pharmaceutical CMO and CDMO Market Size by Country 10.3.1 Middle East & Africa Pharmaceutical CMO and CDMO Consumption Value by



Country (2018-2029)

- 10.3.2 Turkey Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
- 10.3.3 Saudi Arabia Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)
 - 10.3.4 UAE Pharmaceutical CMO and CDMO Market Size and Forecast (2018-2029)

11 MARKET DYNAMICS

- 11.1 Pharmaceutical CMO and CDMO Market Drivers
- 11.2 Pharmaceutical CMO and CDMO Market Restraints
- 11.3 Pharmaceutical CMO and CDMO Trends Analysis
- 11.4 Porters Five Forces Analysis
 - 11.4.1 Threat of New Entrants
 - 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
- 11.5 Influence of COVID-19 and Russia-Ukraine War
 - 11.5.1 Influence of COVID-19
 - 11.5.2 Influence of Russia-Ukraine War

12 INDUSTRY CHAIN ANALYSIS

- 12.1 Pharmaceutical CMO and CDMO Industry Chain
- 12.2 Pharmaceutical CMO and CDMO Upstream Analysis
- 12.3 Pharmaceutical CMO and CDMO Midstream Analysis
- 12.4 Pharmaceutical CMO and CDMO Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

- 14.1 Methodology
- 14.2 Research Process and Data Source
- 14.3 Disclaimer



List Of Tables

LIST OF TABLES

- Table 1. Global Pharmaceutical CMO and CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Table 2. Global Pharmaceutical CMO and CDMO Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
- Table 3. Global Pharmaceutical CMO and CDMO Consumption Value by Region (2018-2023) & (USD Million)
- Table 4. Global Pharmaceutical CMO and CDMO Consumption Value by Region (2024-2029) & (USD Million)
- Table 5. Lonza Company Information, Head Office, and Major Competitors
- Table 6. Lonza Major Business
- Table 7. Lonza Pharmaceutical CMO and CDMO Product and Solutions
- Table 8. Lonza Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 9. Lonza Recent Developments and Future Plans
- Table 10. Catalent Company Information, Head Office, and Major Competitors
- Table 11. Catalent Major Business
- Table 12. Catalent Pharmaceutical CMO and CDMO Product and Solutions
- Table 13. Catalent Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 14. Catalent Recent Developments and Future Plans
- Table 15. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors
- Table 16. Thermo Fisher Scientific Major Business
- Table 17. Thermo Fisher Scientific Pharmaceutical CMO and CDMO Product and Solutions
- Table 18. Thermo Fisher Scientific Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 19. Thermo Fisher Scientific Recent Developments and Future Plans
- Table 20. Samsung Biologics Company Information, Head Office, and Major Competitors
- Table 21. Samsung Biologics Major Business
- Table 22. Samsung Biologics Pharmaceutical CMO and CDMO Product and Solutions
- Table 23. Samsung Biologics Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 24. Samsung Biologics Recent Developments and Future Plans



- Table 25. Fareva Company Information, Head Office, and Major Competitors
- Table 26. Fareva Major Business
- Table 27. Fareva Pharmaceutical CMO and CDMO Product and Solutions
- Table 28. Fareva Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 29. Fareva Recent Developments and Future Plans
- Table 30. WuXi AppTech Company Information, Head Office, and Major Competitors
- Table 31. WuXi AppTech Major Business
- Table 32. WuXi AppTech Pharmaceutical CMO and CDMO Product and Solutions
- Table 33. WuXi AppTech Pharmaceutical CMO and CDMO Revenue (USD Million),
- Gross Margin and Market Share (2018-2023)
- Table 34. WuXi AppTech Recent Developments and Future Plans
- Table 35. WuXi Biologics Company Information, Head Office, and Major Competitors
- Table 36. WuXi Biologics Major Business
- Table 37. WuXi Biologics Pharmaceutical CMO and CDMO Product and Solutions
- Table 38. WuXi Biologics Pharmaceutical CMO and CDMO Revenue (USD Million),
- Gross Margin and Market Share (2018-2023)
- Table 39. WuXi Biologics Recent Developments and Future Plans
- Table 40. Siegfried Company Information, Head Office, and Major Competitors
- Table 41. Siegfried Major Business
- Table 42. Siegfried Pharmaceutical CMO and CDMO Product and Solutions
- Table 43. Siegfried Pharmaceutical CMO and CDMO Revenue (USD Million), Gross
- Margin and Market Share (2018-2023)
- Table 44. Siegfried Recent Developments and Future Plans
- Table 45. FUJIFILM Diosynth Biotechnologies Company Information, Head Office, and Major Competitors
- Table 46. FUJIFILM Diosynth Biotechnologies Major Business
- Table 47. FUJIFILM Diosynth Biotechnologies Pharmaceutical CMO and CDMO
- **Product and Solutions**
- Table 48. FUJIFILM Diosynth Biotechnologies Pharmaceutical CMO and CDMO
- Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 49. FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
- Table 50. Asymchem Company Information, Head Office, and Major Competitors
- Table 51. Asymchem Major Business
- Table 52. Asymchem Pharmaceutical CMO and CDMO Product and Solutions
- Table 53. Asymchem Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 54. Asymchem Recent Developments and Future Plans
- Table 55. Pfizer CentreOne Company Information, Head Office, and Major Competitors



- Table 56. Pfizer CentreOne Major Business
- Table 57. Pfizer CentreOne Pharmaceutical CMO and CDMO Product and Solutions
- Table 58. Pfizer CentreOne Pharmaceutical CMO and CDMO Revenue (USD Million),
- Gross Margin and Market Share (2018-2023)
- Table 59. Pfizer CentreOne Recent Developments and Future Plans
- Table 60. Delpharm Company Information, Head Office, and Major Competitors
- Table 61. Delpharm Major Business
- Table 62. Delpharm Pharmaceutical CMO and CDMO Product and Solutions
- Table 63. Delpharm Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 64. Delpharm Recent Developments and Future Plans
- Table 65. Recipharm Company Information, Head Office, and Major Competitors
- Table 66. Recipharm Major Business
- Table 67. Recipharm Pharmaceutical CMO and CDMO Product and Solutions
- Table 68. Recipharm Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 69. Recipharm Recent Developments and Future Plans
- Table 70. AGC Pharma Chemicals Company Information, Head Office, and Major Competitors
- Table 71. AGC Pharma Chemicals Major Business
- Table 72. AGC Pharma Chemicals Pharmaceutical CMO and CDMO Product and Solutions
- Table 73. AGC Pharma Chemicals Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 74. AGC Pharma Chemicals Recent Developments and Future Plans
- Table 75. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
- Table 76. Boehringer Ingelheim Major Business
- Table 77. Boehringer Ingelheim Pharmaceutical CMO and CDMO Product and Solutions
- Table 78. Boehringer Ingelheim Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 79. Boehringer Ingelheim Recent Developments and Future Plans
- Table 80. Vetter Company Information, Head Office, and Major Competitors
- Table 81. Vetter Major Business
- Table 82. Vetter Pharmaceutical CMO and CDMO Product and Solutions
- Table 83. Vetter Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 84. Vetter Recent Developments and Future Plans



- Table 85. Curia Company Information, Head Office, and Major Competitors
- Table 86. Curia Major Business
- Table 87. Curia Pharmaceutical CMO and CDMO Product and Solutions
- Table 88. Curia Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 89. Curia Recent Developments and Future Plans
- Table 90. Aenova Company Information, Head Office, and Major Competitors
- Table 91. Aenova Major Business
- Table 92. Aenova Pharmaceutical CMO and CDMO Product and Solutions
- Table 93. Aenova Pharmaceutical CMO and CDMO Revenue (USD Million), Gross
- Margin and Market Share (2018-2023)
- Table 94. Aenova Recent Developments and Future Plans
- Table 95. Porton Company Information, Head Office, and Major Competitors
- Table 96. Porton Major Business
- Table 97. Porton Pharmaceutical CMO and CDMO Product and Solutions
- Table 98. Porton Pharmaceutical CMO and CDMO Revenue (USD Million), Gross
- Margin and Market Share (2018-2023)
- Table 99. Porton Recent Developments and Future Plans
- Table 100. Piramal Company Information, Head Office, and Major Competitors
- Table 101. Piramal Major Business
- Table 102. Piramal Pharmaceutical CMO and CDMO Product and Solutions
- Table 103. Piramal Pharmaceutical CMO and CDMO Revenue (USD Million), Gross
- Margin and Market Share (2018-2023)
- Table 104. Piramal Recent Developments and Future Plans
- Table 105. Strides Pharma Company Information, Head Office, and Major Competitors
- Table 106. Strides Pharma Major Business
- Table 107. Strides Pharma Pharmaceutical CMO and CDMO Product and Solutions
- Table 108. Strides Pharma Pharmaceutical CMO and CDMO Revenue (USD Million),
- Gross Margin and Market Share (2018-2023)
- Table 109. Strides Pharma Recent Developments and Future Plans
- Table 110. NextPharma Company Information, Head Office, and Major Competitors
- Table 111. NextPharma Major Business
- Table 112. NextPharma Pharmaceutical CMO and CDMO Product and Solutions
- Table 113. NextPharma Pharmaceutical CMO and CDMO Revenue (USD Million),
- Gross Margin and Market Share (2018-2023)
- Table 114. NextPharma Recent Developments and Future Plans
- Table 115. Famar Company Information, Head Office, and Major Competitors
- Table 116. Famar Major Business
- Table 117. Famar Pharmaceutical CMO and CDMO Product and Solutions



- Table 118. Famar Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 119. Famar Recent Developments and Future Plans
- Table 120. Jubilant Company Information, Head Office, and Major Competitors
- Table 121. Jubilant Major Business
- Table 122. Jubilant Pharmaceutical CMO and CDMO Product and Solutions
- Table 123. Jubilant Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 124. Jubilant Recent Developments and Future Plans
- Table 125. Alcami Company Information, Head Office, and Major Competitors
- Table 126. Alcami Major Business
- Table 127. Alcami Pharmaceutical CMO and CDMO Product and Solutions
- Table 128. Alcami Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 129. Alcami Recent Developments and Future Plans
- Table 130. Euroapi Company Information, Head Office, and Major Competitors
- Table 131. Euroapi Major Business
- Table 132. Euroapi Pharmaceutical CMO and CDMO Product and Solutions
- Table 133. Euroapi Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 134. Euroapi Recent Developments and Future Plans
- Table 135. Eurofins Company Information, Head Office, and Major Competitors
- Table 136. Eurofins Major Business
- Table 137. Eurofins Pharmaceutical CMO and CDMO Product and Solutions
- Table 138. Eurofins Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 139. Eurofins Recent Developments and Future Plans
- Table 140. Avid Bioservices Company Information, Head Office, and Major Competitors
- Table 141. Avid Bioservices Major Business
- Table 142. Avid Bioservices Pharmaceutical CMO and CDMO Product and Solutions
- Table 143. Avid Bioservices Pharmaceutical CMO and CDMO Revenue (USD Million),
- Gross Margin and Market Share (2018-2023)
- Table 144. Avid Bioservices Recent Developments and Future Plans
- Table 145. BioVectra Company Information, Head Office, and Major Competitors
- Table 146. BioVectra Major Business
- Table 147. BioVectra Pharmaceutical CMO and CDMO Product and Solutions
- Table 148. BioVectra Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 149. BioVectra Recent Developments and Future Plans



- Table 150. CPL Company Information, Head Office, and Major Competitors
- Table 151. CPL Major Business
- Table 152. CPL Pharmaceutical CMO and CDMO Product and Solutions
- Table 153. CPL Pharmaceutical CMO and CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 154. CPL Recent Developments and Future Plans
- Table 155. Global Pharmaceutical CMO and CDMO Revenue (USD Million) by Players (2018-2023)
- Table 156. Global Pharmaceutical CMO and CDMO Revenue Share by Players (2018-2023)
- Table 157. Breakdown of Pharmaceutical CMO and CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 158. Market Position of Players in Pharmaceutical CMO and CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
- Table 159. Head Office of Key Pharmaceutical CMO and CDMO Players
- Table 160. Pharmaceutical CMO and CDMO Market: Company Product Type Footprint
- Table 161. Pharmaceutical CMO and CDMO Market: Company Product Application Footprint
- Table 162. Pharmaceutical CMO and CDMO New Market Entrants and Barriers to Market Entry
- Table 163. Pharmaceutical CMO and CDMO Mergers, Acquisition, Agreements, and Collaborations
- Table 164. Global Pharmaceutical CMO and CDMO Consumption Value (USD Million) by Type (2018-2023)
- Table 165. Global Pharmaceutical CMO and CDMO Consumption Value Share by Type (2018-2023)
- Table 166. Global Pharmaceutical CMO and CDMO Consumption Value Forecast by Type (2024-2029)
- Table 167. Global Pharmaceutical CMO and CDMO Consumption Value by Application (2018-2023)
- Table 168. Global Pharmaceutical CMO and CDMO Consumption Value Forecast by Application (2024-2029)
- Table 169. North America Pharmaceutical CMO and CDMO Consumption Value by Type (2018-2023) & (USD Million)
- Table 170. North America Pharmaceutical CMO and CDMO Consumption Value by Type (2024-2029) & (USD Million)
- Table 171. North America Pharmaceutical CMO and CDMO Consumption Value by Application (2018-2023) & (USD Million)
- Table 172. North America Pharmaceutical CMO and CDMO Consumption Value by



Application (2024-2029) & (USD Million)

Table 173. North America Pharmaceutical CMO and CDMO Consumption Value by Country (2018-2023) & (USD Million)

Table 174. North America Pharmaceutical CMO and CDMO Consumption Value by Country (2024-2029) & (USD Million)

Table 175. Europe Pharmaceutical CMO and CDMO Consumption Value by Type (2018-2023) & (USD Million)

Table 176. Europe Pharmaceutical CMO and CDMO Consumption Value by Type (2024-2029) & (USD Million)

Table 177. Europe Pharmaceutical CMO and CDMO Consumption Value by Application (2018-2023) & (USD Million)

Table 178. Europe Pharmaceutical CMO and CDMO Consumption Value by Application (2024-2029) & (USD Million)

Table 179. Europe Pharmaceutical CMO and CDMO Consumption Value by Country (2018-2023) & (USD Million)

Table 180. Europe Pharmaceutical CMO and CDMO Consumption Value by Country (2024-2029) & (USD Million)

Table 181. Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value by Type (2018-2023) & (USD Million)

Table 182. Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value by Type (2024-2029) & (USD Million)

Table 183. Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value by Application (2018-2023) & (USD Million)

Table 184. Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value by Application (2024-2029) & (USD Million)

Table 185. Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value by Region (2018-2023) & (USD Million)

Table 186. Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value by Region (2024-2029) & (USD Million)

Table 187. South America Pharmaceutical CMO and CDMO Consumption Value by Type (2018-2023) & (USD Million)

Table 188. South America Pharmaceutical CMO and CDMO Consumption Value by Type (2024-2029) & (USD Million)

Table 189. South America Pharmaceutical CMO and CDMO Consumption Value by Application (2018-2023) & (USD Million)

Table 190. South America Pharmaceutical CMO and CDMO Consumption Value by Application (2024-2029) & (USD Million)

Table 191. South America Pharmaceutical CMO and CDMO Consumption Value by Country (2018-2023) & (USD Million)



Table 192. South America Pharmaceutical CMO and CDMO Consumption Value by Country (2024-2029) & (USD Million)

Table 193. Middle East & Africa Pharmaceutical CMO and CDMO Consumption Value by Type (2018-2023) & (USD Million)

Table 194. Middle East & Africa Pharmaceutical CMO and CDMO Consumption Value by Type (2024-2029) & (USD Million)

Table 195. Middle East & Africa Pharmaceutical CMO and CDMO Consumption Value by Application (2018-2023) & (USD Million)

Table 196. Middle East & Africa Pharmaceutical CMO and CDMO Consumption Value by Application (2024-2029) & (USD Million)

Table 197. Middle East & Africa Pharmaceutical CMO and CDMO Consumption Value by Country (2018-2023) & (USD Million)

Table 198. Middle East & Africa Pharmaceutical CMO and CDMO Consumption Value by Country (2024-2029) & (USD Million)

Table 199. Pharmaceutical CMO and CDMO Raw Material

Table 200. Key Suppliers of Pharmaceutical CMO and CDMO Raw Materials



List Of Figures

LIST OF FIGURES

Figure 1. Pharmaceutical CMO and CDMO Picture

Figure 2. Global Pharmaceutical CMO and CDMO Consumption Value by Type, (USD

Million), 2018 & 2022 & 2029

Figure 3. Global Pharmaceutical CMO and CDMO Consumption Value Market Share by

Type in 2022

Figure 4. API CMO and CDMO

Figure 5. FDF CMO and CDMO

Figure 6. Packaging CMO

Figure 7. Clinical CDMO

Figure 8. Global Pharmaceutical CMO and CDMO Consumption Value by Type, (USD

Million), 2018 & 2022 & 2029

Figure 9. Pharmaceutical CMO and CDMO Consumption Value Market Share by

Application in 2022

Figure 10. Pharmaceutical Company Picture

Figure 11. Biotechnology Company Picture

Figure 12. Other Picture

Figure 13. Global Pharmaceutical CMO and CDMO Consumption Value, (USD Million):

2018 & 2022 & 2029

Figure 14. Global Pharmaceutical CMO and CDMO Consumption Value and Forecast

(2018-2029) & (USD Million)

Figure 15. Global Market Pharmaceutical CMO and CDMO Consumption Value (USD

Million) Comparison by Region (2018 & 2022 & 2029)

Figure 16. Global Pharmaceutical CMO and CDMO Consumption Value Market Share

by Region (2018-2029)

Figure 17. Global Pharmaceutical CMO and CDMO Consumption Value Market Share

by Region in 2022

Figure 18. North America Pharmaceutical CMO and CDMO Consumption Value

(2018-2029) & (USD Million)

Figure 19. Europe Pharmaceutical CMO and CDMO Consumption Value (2018-2029) &

(USD Million)

Figure 20. Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value

(2018-2029) & (USD Million)

Figure 21. South America Pharmaceutical CMO and CDMO Consumption Value

(2018-2029) & (USD Million)

Figure 22. Middle East and Africa Pharmaceutical CMO and CDMO Consumption Value



(2018-2029) & (USD Million)

Figure 23. Global Pharmaceutical CMO and CDMO Revenue Share by Players in 2022

Figure 24. Pharmaceutical CMO and CDMO Market Share by Company Type (Tier 1,

Tier 2 and Tier 3) in 2022

Figure 25. Global Top 3 Players Pharmaceutical CMO and CDMO Market Share in 2022

Figure 26. Global Top 6 Players Pharmaceutical CMO and CDMO Market Share in 2022

Figure 27. Global Pharmaceutical CMO and CDMO Consumption Value Share by Type (2018-2023)

Figure 28. Global Pharmaceutical CMO and CDMO Market Share Forecast by Type (2024-2029)

Figure 29. Global Pharmaceutical CMO and CDMO Consumption Value Share by Application (2018-2023)

Figure 30. Global Pharmaceutical CMO and CDMO Market Share Forecast by Application (2024-2029)

Figure 31. North America Pharmaceutical CMO and CDMO Consumption Value Market Share by Type (2018-2029)

Figure 32. North America Pharmaceutical CMO and CDMO Consumption Value Market Share by Application (2018-2029)

Figure 33. North America Pharmaceutical CMO and CDMO Consumption Value Market Share by Country (2018-2029)

Figure 34. United States Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 35. Canada Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 36. Mexico Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 37. Europe Pharmaceutical CMO and CDMO Consumption Value Market Share by Type (2018-2029)

Figure 38. Europe Pharmaceutical CMO and CDMO Consumption Value Market Share by Application (2018-2029)

Figure 39. Europe Pharmaceutical CMO and CDMO Consumption Value Market Share by Country (2018-2029)

Figure 40. Germany Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 41. France Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 42. United Kingdom Pharmaceutical CMO and CDMO Consumption Value



(2018-2029) & (USD Million)

Figure 43. Russia Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 44. Italy Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 45. Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value Market Share by Type (2018-2029)

Figure 46. Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value Market Share by Application (2018-2029)

Figure 47. Asia-Pacific Pharmaceutical CMO and CDMO Consumption Value Market Share by Region (2018-2029)

Figure 48. China Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 49. Japan Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 50. South Korea Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 51. India Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 52. Southeast Asia Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 53. Australia Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 54. South America Pharmaceutical CMO and CDMO Consumption Value Market Share by Type (2018-2029)

Figure 55. South America Pharmaceutical CMO and CDMO Consumption Value Market Share by Application (2018-2029)

Figure 56. South America Pharmaceutical CMO and CDMO Consumption Value Market Share by Country (2018-2029)

Figure 57. Brazil Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 58. Argentina Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 59. Middle East and Africa Pharmaceutical CMO and CDMO Consumption Value Market Share by Type (2018-2029)

Figure 60. Middle East and Africa Pharmaceutical CMO and CDMO Consumption Value Market Share by Application (2018-2029)

Figure 61. Middle East and Africa Pharmaceutical CMO and CDMO Consumption Value Market Share by Country (2018-2029)



Figure 62. Turkey Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 63. Saudi Arabia Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 64. UAE Pharmaceutical CMO and CDMO Consumption Value (2018-2029) & (USD Million)

Figure 65. Pharmaceutical CMO and CDMO Market Drivers

Figure 66. Pharmaceutical CMO and CDMO Market Restraints

Figure 67. Pharmaceutical CMO and CDMO Market Trends

Figure 68. Porters Five Forces Analysis

Figure 69. Manufacturing Cost Structure Analysis of Pharmaceutical CMO and CDMO in 2022

Figure 70. Manufacturing Process Analysis of Pharmaceutical CMO and CDMO

Figure 71. Pharmaceutical CMO and CDMO Industrial Chain

Figure 72. Methodology

Figure 73. Research Process and Data Source



I would like to order

Product name: Global Pharmaceutical CMO and CDMO Market 2023 by Company, Regions, Type and

Application, Forecast to 2029

Product link: https://marketpublishers.com/r/GB2813B4E2A6EN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GB2813B4E2A6EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

| Last name: | |
|---------------|---------------------------|
| Email: | |
| Company: | |
| Address: | |
| City: | |
| Zip code: | |
| Country: | |
| Tel: | |
| Fax: | |
| Your message: | |
| | |
| | |
| | |
| | **All fields are required |
| | Custumer signature |
| | |

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

